Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$4.19 ▼ -0.15
(-3.46%)
MKT CAP: $78.8M • VOL: 77.8K
52W L $3 52W H $13
ROARABLE / RQD
D- • 35/100
PIOTROSKI
6 / 9
OM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $119.5M | $113.7M | $130.4M |
| YoY Revenue Growth % | +5.1% | -12.8% | — |
| Gross Profit | $46.8M | $38.6M | — |
| Gross Margin % | 39.1% | 33.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$66.7M | -$113.4M | -$169.8M |
| Operating Margin % | -55.8% | -80.0% | -80.0% |
| Net Income (GAAP) | -$81.7M | -$128.0M | -$172.8M |
| EBITDA (Normalized) | -$66.1M | -$112.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$46.3M | -$116.3M | -$131.4M |
| Capital Expenditures (CapEx) | $798.0K | $912.0K | — |
| Free Cash Flow (FCF) | -$47.1M | -$117.2M | -$131.4M |
| FCF Margin % | -39.4% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -28.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $35.0M | $124.0M | — |
| Total Debt (Short + Long Term) | $96.2M | $197.4M | — |
| Total Stockholders' Equity | $127.0M | $26.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OM.